Comorbidity mattered more than chronological age after proton therapy for hepatocellular carcinoma
Age ≥75 did not independently predict outcomes after proton therapy for HCC, while CCI ≥3 was associated with more than threefold higher mortality.
Tag
hepatocellular
Adding CyberKnife SBRT to lenvatinib and tislelizumab tracked with longer survival in HCC
IPTW-weighted response was 71.1% versus 37.6%, with median survival 23.0 versus 15.6 months after adding SBRT.
VMAT lattice radiotherapy produced 65% median shrinkage in bulky hepatocellular carcinoma
Twelve VMAT lattice courses produced 65% median tumor shrinkage and no local progression during short follow-up in bulky hepatocellular carcinoma.
DCAF4 promoted hepatocellular carcinoma resistance to iodine-125 brachytherapy
DCAF4 activated NRF2-dependent antioxidant defence and protected hepatocellular carcinoma against iodine-125 brachytherapy in preclinical models.
Intratumoral polyvinyl chloride was associated with radioresistance in hepatocellular carcinoma
PVC was detected in 37 of 72 HCC tumors and was associated with poorer response and progression-free survival after SBRT, immunotherapy, and bevacizumab.
Magnetic resonance imaging after hepatocellular carcinoma stereotactic body radiation therapy requires serial assessment
After stereotactic body radiation therapy for hepatocellular carcinoma, magnetic resonance response evolved over months, making early enhancement alone unreliable.
Respiratory gating limited accumulated motion-related dose errors in proton therapy for hepatocellular carcinoma
Respiratory gating more than halved cranio-caudal motion, while motion-related target-dose deviations largely diminished after accumulation across more than three fractions.